TY-JUR T1 - 肺多药抗性结核的结果：A 6 - YR后续研究JF - 欧洲呼吸期刊JO - EUR RESPIR J SP - 980 LP - 985 DO - 10.1183 / 09031936.06.00125705 VL - 28是 - 5AU - Chiang, C-Y. AU - Enarson, D. A. AU - Yu, M-C. AU - Bai, K-J. AU - Huang, R-M. AU - Hsu, C-J. AU - Suo, J. AU - Lin, T-P. Y1 - 2006/11/01 UR - //www.qdcxjkg.com/content/28/5/980.abstract N2 - A retrospective study was performed to determine factors associated with the outcome of pulmonary multidrug-resistant tuberculosis (MDR-TB) in Taipei, Taiwan. All patients newly diagnosed with pulmonary MDR-TB in a referral centre from 1992–1996 were enrolled and their outcome over the subsequent 6 yrs was determined. A total of 299 patients were identified, comprising 215 (71.9%) males and 84 (28.1%) females with a mean age of 47.3 yrs. The patients received a mean of 3.7 effective drugs. Out of the 299 patients, 153 (51.2%) were cured, 31 (10.4%) failed, 28 (9.4%) died and 87 (29.1%) defaulted. Of the 125 patients receiving second-line drugs with ofloxacin, 74 (59.2%) were cured. Those who received ofloxacin had a lower risk of relapse than those receiving only first-line drugs (hazard ratio (HR) 0.16, 95% confidence interval (CI) 0.03–0.81) and a lower risk of TB-related death than those receiving second-line drugs but not ofloxacin (adjusted HR 0.50, 95% CI 0.31–0.82). In conclusion, multidrug-resistant tuberculosis patients who received ofloxacin were more likely to be cured, and were less likely to die, fail or relapse. The utility of new-generation fluoroquinolones, such as moxifloxacin, in the treatment of multidrug-resistant tuberculosis needs to be evaluated. Default from treatment is a major challenge in the treatment of multidrug-resistant tuberculosis. ER -